Dear Editor,

We read a recent article in your journal regarding the use of benzodiazepines in Portugal.1 According to the authors, only eleven different benzodiazepine types were prescribed to patients.

We were surprised that not a single patient was being prescribed with any of the other nine types of benzodiazepines which are still commercially available in Portugal.2 We also wondered about the other five types of benzodiazepines which have been withdrawn from the market in Portugal.3 It is not clear how the authors excluded the present and past abuse of these particular substances. We were also surprised to see that patients had not carried out urine or blood tests to confirm the drug use. What a patient tells us in a questionnaire is always some kind of subjective information that should, whenever possible, be cross-checked with objective information.

The article discussion missed the important issue of the LOT benzodiazepines: lorazepam, oxazepam and temazepam. Another useful mnemonic for these molecules would be OTL: other than liver. These three drugs have no active metabolites after hepatic conjugation, and therefore present minimally affected half-lives in patients with liver disease,4 e.g., hepatic cirrhosis due to alcohol and/or chronic viral infection.

Last, but not least, we would like to remind the stars of the Liège model,5 which has been used for decades for the purposes of psychopharmacological comparison among the different types of benzodiazepines. We recently adapted this classic visual model where each of the five arms of a pentagram star corresponds to a different psychopharmacological characteristic, e.g., somatic anxiolytic, psychic anxiolytic, antiepileptic, myorelaxant and hypnotic (Fig. 1).

This model allows researchers to classify any benzodiazepine with ecological characteristic, e.g., somatic anxiolytic, psychic anxiolytic, antiepileptic, myorelaxant and hypnotic (Fig. 1). With this zero (null) to five (very powerful) scale, clinical researchers are thus able to classify any benzodiazepine with an intrinsically unique signature. Although we were quite disappointed for not finding a citation of this model in the aforementioned article, we would like to share it with the readers, hoping that it will help them in their clinical practice.

Yours sincerely,

Eurico Castro ALVES, João OLIVEIRA, Mariana GINESTAL, Catarina FERREIRA, Ana POVO.

REFERENCES

Figure 1 – Stars of Liège model: a psychopharmacological signature for every benzodiazepine (adapted from Cloos and Bocquet, 2013)

COMPETING INTERESTS
The authors have declared that no competing interests exist.

FUNDING SOURCES
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

REFERENCES